Research Triangle Park, North Carolina, and Pleasanton, California, October 13, 2026 / PRNewswire / – IQVIA ( NYSE : IQV ) and Veeva Systems ( NYSE : VEEV ) announced today that they are expanding their cooperative relationship. IQVIA has selected Veeva CTMS , eTMF , Study Startup , and Site Connect as standard enterprise applications, which will be used in all clinical development studies at IQVIA . This marks a further extension of the EDC cooperative relationship previously announced by both parties.
IQVIA and Veeva indicate that both parties will jointly provide leading clinical research capabilities to help clients accelerate and improve the efficiency of trials, strengthen the core position of research centers, and make more informed decisions, thereby enabling patients to access breakthrough therapies more quickly. IQVIA also states that for sponsors who wish to utilize the full Veeva technology stack, all Veeva clinical solutions are also available through IQVIA.
IQVIA, President of R&D Solutions, Richard Staub stated: "By integrating the strengths of both companies, we have provided clinical teams with a more interconnected way of working, built on the foundation of seamless integration of our technologies. At the same time, it is equally important that customers can still freely choose the EDC, RTSM, and eCOA technologies and solutions that best meet their needs, which also include the innovative capabilities of IQVIA."
Veeva Founder and CEO Peter Gassner stated: "This is an exciting development since IQVIA and Veeva announced their partnership last year, and since then we have been working together on this project. We are committed to supporting the smooth integration of products and services to benefit our customers and to improve patients' access to innovative solutions."
The company stated that more information can be obtained at the Veeva R &D and Quality Summit to be held in Boston from October 20th to 21st.
About IQVIA
IQVIA ( NYSE : IQV ) is one of the world's leading providers of clinical research services, business information, and healthcare intelligence, serving the life sciences and healthcare industries. IQVIA states that its portfolio of solutions is driven by IQVIA Connected Intelligence ™, combining high-quality healthcare data, Healthcare-grade AI ®, advanced analytics, the latest technologies, and extensive industry expertise to provide actionable insights and services. IQVIA asserts that the company is committed to using artificial intelligence responsibly, with its AI capabilities built on best practices in privacy protection, regulatory compliance, and patient safety, offering AI solutions that meet the high standards of the industry in terms of reliability, scalability, and accuracy.
IQVIA indicates that the company has approximately 94,000 employees in over 100 countries, comprising experts in fields such as healthcare, life sciences, data science, technology, and operational excellence. The company is committed to accelerating the development and commercialization of innovative medical therapies to help improve clinical outcomes for patients worldwide and enhance public health.
IQVIA also indicates that the company is in a leading position globally in protecting patient privacy. By utilizing a wide range of technologies and privacy protection measures, the company generates and analyzes large amounts of data to help participants in the healthcare industry identify disease patterns and correlate them with the precise treatments and therapies required for better outcomes. IQVIA states that its insights and execution capabilities enable biotechnology, medical device, and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders to better understand diseases, human behavior, and scientific advancements, thereby advancing the process of healing. For more information, please visit www.iqvia.com.
About Veeva Systems
Veeva provides cloud platforms for the life sciences industry, covering applications, intelligent agents, data, and consulting services. Veeva indicates that the company focuses on innovation, excellence in products, and customer success, with over 1,500 clients, including the world's largest biopharmaceutical companies and emerging biotech enterprises. As a for-profit company, Veeva states that it is committed to balancing the interests of all stakeholders as much as possible, including customers, employees, shareholders, and the industries it serves. For more information, please visit veeva.com.
Veeva Forward-looking Statement
This press release contains forward-looking statements regarding Veeva products and services, as well as the expected benefits from using such products and services. It also includes forward-looking statements regarding the partnership between Veeva and IQVIA and the expected benefits of this partnership. These statements are based on the company's current expectations. Actual results may differ significantly from those described in this press release, and the company has no obligation to update these statements. There are numerous risks that may have an adverse effect on the company's performance, including those mentioned in the 10-Q report for the fiscal quarter ending July 31, 2026, which can be found at the relevant link (a summary of risks that may affect the company's business is on pages 33 and 34), as well as in subsequent documents submitted to the U.S. Securities and Exchange Commission (SEC). These related documents can be viewed at sec.gov.
